MarginsXMarginsX
Home › Markets › Health Care › BBOT

BridgeBio Oncology Therapeutics Inc. Common Stock (BBOT)

BBOT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$1.98
-7.48% on the day
Market cap
$158.9M
Micro cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerBBOT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2024
SEC CIK0001869105
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
6.1 months
$76.5M cash at September 30, 2026
Share count, 1 year
+0.3%
2025-11-07 to 2026-11-05
Going-concern doubt
No
10-Q filed November 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-10
Cash and burn$76.5M cash; operating cash flow -$37.7M a quarter.Report 2026-09-30
Shares outstanding80,251,267 (2026-11-05); 79,988,687 a year earlier.Cover page 2026-11-05
Reverse splits, 3 years1; latest on 2025-08-13Source 2025-08-13
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-09-01
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte & Touche LLP, San Francisco, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-08-13
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$34.2M-$28.4M$76.5MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q2 2026
2026-06-30
Not filed-$56.5M-$44.4M$54.1MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2026
2026-03-31
Not filed-$42.1M-$35.9M$52.7M$716KNeeds four quarters10-Q 2026-11-10
Q4 2025
2025-12-31
Not filed-$38.8M-$42.2M$373.7M$534KNeeds four quarters10-K 2026-03-05
Q3 2025
2025-09-30
Not filed-$44.8M-$28.8M$408.7M$691KNeeds four quarters10-Q 2026-11-10
Q2 2025
2025-06-30
Not filed-$28.4M-$23.3M$31.6MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q1 2025
2025-03-31
Not filed-$22.1M-$19.6M$26.3MNo debt tagsNeeds four quarters10-Q 2026-11-10
Q4 2024
2024-12-31
Not filed-$19.7M-$15.0M$30.9M$483KNeeds four quarters10-K 2026-03-05

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-09-01
Latest annual report10-K2026-03-05
Latest quarterly / interim10-Q2026-11-10
Latest current report8-K2026-11-10
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 189 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+4.9%
1 month-27.5%
3 months-76.8%
Year to date-82.9%
1 year-82.7%
From 52-week high-84.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ADCTADC Therapeutics SA Common Shares$1.25-6.72%$159.7M
ZNTLZentalis Pharmaceuticals Inc.$1.60-5.88%$157.2M
ELDNEledon Pharmaceuticals Inc.$1.97-6.86%$166.4M
PRQRProQR Therapeutics N.V.$1.18-16.31%$166.5M
PYXSPyxis Oncology Inc.$1.41-10.76%$168.6M
ORMPOramed Pharmaceuticals Inc.$3.90+5.12%$169.6M
ANTXAN2 Therapeutics Inc.$4.47-1.76%$169.6M
ABEOAbeona Therapeutics Inc.$2.60+7.44%$148.6M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier